Cargando…

Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI

BACKGROUND AND THE PURPOSE OF THE STUDY: Biodegradable Poly(caprolactone fumarate) (PCLF) has been used as bioresorbable sutures. In this study, doxorubicin HCl (Dox) loaded PCLF nanoparticles were prepared and characterized. MATERIAL AND METHODS: PCLFs were synthesized by polycondensation of PCL di...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokri, N., Akbari Javar, H., Fouladdel, Sh., Khalaj, A., Khoshayand, MR., Dinarvand, R., Atyabi, F., Nomani, A., Azizi, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232073/
https://www.ncbi.nlm.nih.gov/pubmed/22615635
_version_ 1782218318211448832
author Shokri, N.
Akbari Javar, H.
Fouladdel, Sh.
Khalaj, A.
Khoshayand, MR.
Dinarvand, R.
Atyabi, F.
Nomani, A.
Azizi, E.
author_facet Shokri, N.
Akbari Javar, H.
Fouladdel, Sh.
Khalaj, A.
Khoshayand, MR.
Dinarvand, R.
Atyabi, F.
Nomani, A.
Azizi, E.
author_sort Shokri, N.
collection PubMed
description BACKGROUND AND THE PURPOSE OF THE STUDY: Biodegradable Poly(caprolactone fumarate) (PCLF) has been used as bioresorbable sutures. In this study, doxorubicin HCl (Dox) loaded PCLF nanoparticles were prepared and characterized. MATERIAL AND METHODS: PCLFs were synthesized by polycondensation of PCL diols (Mws of 530, 1250 and 2000) with fumaryl chloride. The degradation of PCLF in NaOH, water and phosphate buffer saline (PBS), was determined in terms of changes in Mw. Nanoparticles (NPs) were prepared by two methods. In microemulsion polymerization method, dichloromethane containing PCLF and photoinitiator were combined with the water containing surfactants and then the mixture was placed under light for crosslinking. In nanoprecipitation method, the organic solvent containing PCLF was poured into the stirring water. The effect of several variables including concentration of PCLF, polyvinyl alcohol (PVA), Dox and Trypan blue (Trb) and the Mw of PCLF and PVA on NP size and loading were evaluated. RESULT: PCLF 530, 1250 and 2000 in PBS or water were not degraded over 28 days. Nanoprecipitaion method gave spherical (revealed by SEM images) stable NPs of about 225 with narrow size distribution and a zeta potential of −43 mV. The size of NP increased significantly by increase in Mw or concentration of PCLF. Although PVA was not necessary for formation of NPs, but it decreased with NP size. Dox loading and EE were 2.5–6.8% and 15–20%, respectively. Increasing the drug concentration increased the drug loading (DL) and NP size. The entrapment efficiency (EE) for Trb ranged from 1% for PCLF530 to 6% for PCLF2000. An increase in PCLF concentration resulted in an increase in EE. Dox and Trb release showed a burst followed by 80% and 78% release during 3 and 4 days respectively. CONCLUSION: PCLF possessed suitable characteristics for preparation of nanoparticulate drug delivery system such as desired NP size, stability and degradation time. Although PCLF530 NPs were the smallest, but their DL were lower than PCLF1250 and 2000 NPs.
format Online
Article
Text
id pubmed-3232073
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-32320732012-05-21 Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI Shokri, N. Akbari Javar, H. Fouladdel, Sh. Khalaj, A. Khoshayand, MR. Dinarvand, R. Atyabi, F. Nomani, A. Azizi, E. Daru Original Article BACKGROUND AND THE PURPOSE OF THE STUDY: Biodegradable Poly(caprolactone fumarate) (PCLF) has been used as bioresorbable sutures. In this study, doxorubicin HCl (Dox) loaded PCLF nanoparticles were prepared and characterized. MATERIAL AND METHODS: PCLFs were synthesized by polycondensation of PCL diols (Mws of 530, 1250 and 2000) with fumaryl chloride. The degradation of PCLF in NaOH, water and phosphate buffer saline (PBS), was determined in terms of changes in Mw. Nanoparticles (NPs) were prepared by two methods. In microemulsion polymerization method, dichloromethane containing PCLF and photoinitiator were combined with the water containing surfactants and then the mixture was placed under light for crosslinking. In nanoprecipitation method, the organic solvent containing PCLF was poured into the stirring water. The effect of several variables including concentration of PCLF, polyvinyl alcohol (PVA), Dox and Trypan blue (Trb) and the Mw of PCLF and PVA on NP size and loading were evaluated. RESULT: PCLF 530, 1250 and 2000 in PBS or water were not degraded over 28 days. Nanoprecipitaion method gave spherical (revealed by SEM images) stable NPs of about 225 with narrow size distribution and a zeta potential of −43 mV. The size of NP increased significantly by increase in Mw or concentration of PCLF. Although PVA was not necessary for formation of NPs, but it decreased with NP size. Dox loading and EE were 2.5–6.8% and 15–20%, respectively. Increasing the drug concentration increased the drug loading (DL) and NP size. The entrapment efficiency (EE) for Trb ranged from 1% for PCLF530 to 6% for PCLF2000. An increase in PCLF concentration resulted in an increase in EE. Dox and Trb release showed a burst followed by 80% and 78% release during 3 and 4 days respectively. CONCLUSION: PCLF possessed suitable characteristics for preparation of nanoparticulate drug delivery system such as desired NP size, stability and degradation time. Although PCLF530 NPs were the smallest, but their DL were lower than PCLF1250 and 2000 NPs. Tehran University of Medical Sciences 2011 /pmc/articles/PMC3232073/ /pubmed/22615635 Text en © 2011 Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Shokri, N.
Akbari Javar, H.
Fouladdel, Sh.
Khalaj, A.
Khoshayand, MR.
Dinarvand, R.
Atyabi, F.
Nomani, A.
Azizi, E.
Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI
title Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI
title_full Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI
title_fullStr Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI
title_full_unstemmed Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI
title_short Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI
title_sort preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin hci
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232073/
https://www.ncbi.nlm.nih.gov/pubmed/22615635
work_keys_str_mv AT shokrin preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT akbarijavarh preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT fouladdelsh preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT khalaja preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT khoshayandmr preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT dinarvandr preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT atyabif preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT nomania preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci
AT azizie preparationandevaluationofpolycaprolactonefumaratenanoparticlescontainingdoxorubicinhci